Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28901075 | 1.00 | DRD2 (0.41) | DRD2DRD3LIPGEPHX2CTSC | |
| SCHEMBL23462268 | 0.99 | DRD2 (0.41) | DRD2DRD3LIPGEPHX2CTSC | |
| SCHEMBL20137259 | 0.88 | DRD2 (0.44) | DRD2DRD3LIPGEPHX2CTSC | |
| SCHEMBL23489128 | 0.86 | DRD2 (0.45) | DRD2DRD3LIPGEPHX2CTSC | |
| SCHEMBL6374726 | 0.86 | CTSC (0.44) | EPHX2CTSCAGTR2GRIK1GRIA2 | |
| SCHEMBL1006306 | 0.86 | CTSC (0.44) | EPHX2CTSCAGTR2GRIK1GRIA2 | |
| SCHEMBL5802417 | 0.86 | CTSC (0.44) | EPHX2CTSCAGTR2GRIK1GRIA2 | |
| SCHEMBL16920345 | 0.86 | CTSC (0.44) | EPHX2CTSCAGTR2GRIK1GRIA2 | |
| SCHEMBL1006316 | 0.86 | CTSC (0.44) | EPHX2CTSCAGTR2GRIK1GRIA2 | |
| SCHEMBL1768681 | 0.86 | CTSC (0.44) | EPHX2CTSCAGTR2GRIK1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3286169-B1 | PROTAC COMPOUNDS MODULATING RIP2 KINASE ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| US-10435391-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-08 | — | — | US | disclosed |
| US-20180134688-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435391-B2 | Compounds | RIPK2, RIPK1, RIPK4 | DRD2 4536/4885DRD3 4668/4885LIPG 874/4885 |
| US-20180134688-A1 | NOVEL COMPOUNDS | RIPK2, RIPK1, RIPK4 | DRD2 4614/4885DRD3 4705/4885LIPG 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.